BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05130866 (REC-2282 in Progressive Neurofibromatosis Type 2 Mutated Meningiomas): BVCT ex-ante prediction vs. reported outcome

On 11 May 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 5 May 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05130866
Acronym
POPLAR-NF2
Drug Name
REC-2282
Drug MoA
HDAC inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Human Patients
92
Sponsor
Recursion Pharmaceuticals
Phase
Phase 2 Phase 3

Prediction of , index 1592

Prospective Prediction
Prediction Index
1592
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit with inferior-to-microsurgery/radiosurgery efficacy)
Technical Prediction
partial SUCCESS (statistically maybe significant yet very weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
359 days in advance
Readout Data Interpretation
REC2282 failed to achieve statistically significant improvement in efficacy whose further development has thus been discontinued
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas
Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
25
Lead sponsor
Recursion Pharmaceuticals Inc.
Conditions
Neurofibromatosis Type 2
Interventions
DRUG: REC-2282; DRUG: Placebo
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2022-06-20
Primary completion
2025-08-18
Completion
2025-08-18
Primary outcomes
  • Cohort A: Number of Participants with Progression-free survival (PFS) at 6 Months (6 months)
  • Cohort B: Number of Participants with PFS up to 3 years (Up to 3 years)

NCT05130866 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials